Skip to main content

Table 1 Clinicopathologic characteristics

From: Estrogen receptor α as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma

CharacteristicsAll patientsp16+/HPV+ groupp16+/HPV− groupp16−/HPV± groupp value
Sex
 Male101 (89.4%)69 (87.3%)7 (87.5%)25 (96.2%)0.442
 Female12 (10.6%)10 (12.7%)1 (12.5%)1 (3.8%) 
Age (years)
 < 6573 (64.6%)55 (69.6%)5 (62.5%)13 (50%)0.191
 ≥ 6540 (35.4%)24 (20.4%)3 (37.5%)13 (50%) 
Smoking history
 Never38 (33.6%)30 (38.0%)3 (37.5%)5 (19.2%)0.083
 Ever75 (66.4%)49 (62.0%)5 (62.5%)21 (80.8%) 
Subsite
 Palatine tonsil85 (75.2%)68 (86.1%)6 (75%)11 (42.3%)< 0.001*
 Base of tongue14 (12.4%)7 (8.9%)2 (25%)5 (19.2%) 
 Pharyngeal wall7 (6.2%)4 (5.1%)03 (11.5%) 
 Soft palate5 (4.4%)005 (19.2%) 
 Uvula2 (1.8%)002 (7.7%) 
Surgical margina
 Clear64 (80%)39 (72.2%)5 (83.3%)20 (100%)0.084
 Involved16 (20%)15 (27.8%)1 (16.7%)0 
Lymphovascular invasiona
 Absent48 (60%)30 (55.6%)3 (50%)15 (75%)0.478
 Present32 (40%)24 (44.4%)3 (50%)5 (25%) 
Perineural invasiona
 Absent74 (92.5%)50 (92.6%)5 (83.3%)19 (95%)0.784
 Present6 (7.5%)4 (7.4%)1 (16.7%)1 (5%) 
Initial stage (8th AJCC)
 I54 (47.8%)46 (58.2%)3 (37.5%)5 (19.2%)< 0.001*
 II36 (31.9%)27 (34.2%)5 (62.5%)5 (19.2%) 
 III10 (8.8%)6 (7.6%)04 (15.4%) 
 IV13 (11.5%)0012 (46.2%) 
ERα
 Positive40 (35.4%)36 (45.6%)1 (12.5%)3 (11.5%)0.003*
 Negative73 (64.6%)43 (54.4%)7 (87.5%)23 (88.5%) 
ESR1 mRNAb
 Positive16 (15.8%)15 (21.1%)01 (4.3%)0.079
 Negative85 (84.2%)56 (78.9%)7 (100%)22 (95.7%) 
p53 expression
 Altered24 (21.2%)1 (1.3%)3 (37.5%)20 (76.9%)< 0.001*
 Wild type89 (78.8%)78 (98.7%)5 (62.5%)6 (23.1%) 
Total113 (100%)79 (69.9%)8 (7.1%)26 (23%) 
  1. HPV human papillomavirus, AJCC American Joint Committee on Cancer, ERα estrogen receptor, ESR1 estrogen receptor 1
  2. *p < 0.05
  3. aEvaluated only in 80 surgical resection specimens
  4. bEvaluated only in 101 specimens due to RNA quality
\